newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), a